Atomoxetine has 18 known drug interactions based on U.S. FDA drug labeling data. Of these, 1 are contraindicated combinations that should be avoided entirely. 7 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Monoamine Oxidase Inhibitors (Maois), Albuterol, Fluoxetine. Patients taking Atomoxetine should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 18
- Contraindicated
- 1
- Major
- 7
- Moderate
- 7
- Minor
- 1
Contraindicated (1)
- Atomoxetine + Monoamine Oxidase Inhibitors (Maois)— Serious, sometimes fatal reactions including hyperthermia, rigidity, myoclonus, autonomic instability, and mental status…
Major (7)
- Atomoxetine + Albuterol— Beta-2 agonist; action on cardiovascular system can be potentiated by atomoxetine, resulting in increases in heart rate …
- Atomoxetine + Fluoxetine— CYP2D6 inhibitor that increases atomoxetine steady-state plasma concentrations 6- to 8-fold AUC and 3- to 4-fold Cmax in…
- Atomoxetine + Paroxetine— CYP2D6 inhibitor that increases atomoxetine steady-state plasma concentrations 6- to 8-fold AUC and 3- to 4-fold Cmax in…
- Atomoxetine + Phenylephrine Hci— Norepinephrine transport inhibitor that increases the pressor effect of phenylephrine hydrochloride.
- Atomoxetine + Phenylephrine Hydrochloride— Norepinephrine transport inhibitor that increases the pressor effect of phenylephrine hydrochloride.
- Atomoxetine + Phenylephrine Hydrochloride Injection, Solution— Norepinephrine transport inhibitor increases pressor effect of phenylephrine hydrochloride.
- Atomoxetine + Quinidine— CYP2D6 inhibitor that increases atomoxetine steady-state plasma concentrations in extensive metabolizers.
Moderate (7)
- Atomoxetine + Desvenlafaxine— Desvenlafaxine increases atomoxetine levels. Reduce dose by up to one-half with 400 mg desvenlafaxine; no adjustment nee…
- Atomoxetine + Desvenlafaxine Er— Desvenlafaxine increases atomoxetine exposure. Reduce dose by up to one-half with 400 mg desvenlafaxine; no adjustment n…
- Atomoxetine + Desvenlafaxine Succinate— Concomitant use increases exposure (Cmax and AUC). Reduce dose by up to one-half if co-administered with 400 mg desvenla…
- Atomoxetine + Dobutamine— Pressor agent that may cause effects on blood pressure when used with atomoxetine; use with caution.
- Atomoxetine + Dopamine Agonists— Pressor agent that may cause effects on blood pressure when used with atomoxetine; use with caution.
- Atomoxetine + Paroxetine Hydrochloride— Paroxetine inhibits CYP2D6, increasing exposure of atomoxetine. Dosage reduction may be needed.
- Atomoxetine + Paroxetine Hydrochloride Hemihydrate— Paroxetine inhibits CYP2D6 metabolism of atomoxetine, potentially increasing atomoxetine levels.
Minor (1)
- Atomoxetine + Midazolam— CYP3A4 substrate; atomoxetine did not cause clinically important interaction with CYP3A-metabolized drugs.